Recent noteworthy reports on diffuse large B-cell lymphoma (DLBCL) include positive survival results with an antibody-drug conjugate in relapsed/refractory disease, FDA issues with a randomized trial, ...

Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin’s lymphoma. It develops when abnormal B cells rapidly accumulate in lymph nodes, causing painless swelling often in the ...

Key prognostic factors for DLBCL include early failure on chemo-immunotherapy, performance status, and treatment history. Single-arm trials expedite treatment availability but require external ...

T cells are not the only attackersWhen people hear about immunotherapy for blood cancers, many may think of CAR-T cell ...

Ibrutinib, venetoclax plus CD20 monoclonal Ab: Initial results of OASIS II, a prospective randomized phase 2 trial in previously untreated mantle cell lymphoma patients. This is an ASCO Meeting ...

For patients with diffuse large B-cell lymphoma that takes root in the gastrointestinal tract, the first rounds of ...

Please provide your email address to receive an email when new articles are posted on . In this video, Leo I. Gordon, MD, FACP, discusses highlights from a debate at Lymphoma, Leukemia & Myeloma ...

Diffuse large B-cell lymphoma (DLBCL) is a type of cancer that affects white blood cells called lymphocytes. There are two main types of lymphocytes: B-cell lymphocytes (B cells) and T-cell ...